Home・Akciju saraksts・Haemonetics Corp

Haemonetics Corp

Slēgts

SektorsVeselības aprūpe

90.84 0.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

89.32

Max

91.22

Galvenie mērījumi
By Trading Economics
Ienākumi	53M 33M
Pārdošana	-7M 339M
P/E Sektora vidējais	42.456 57.002
EPS	1.14
Peļņas marža	9.727
Darbinieki	3,009
EBITDA	70M 75M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+4.15% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.8M 3.9B
Iepriekšējā atvēršanas cena	90.21
Iepriekšējā slēgšanas cena	90.84

Ziņu noskaņojums

By Acuity

95%

4 / 340 Rangs Healthcare

Haemonetics Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 19:51 UTC

Haemonetics Corp shares are higher today, supported by a positive trend in the Health Care Supplies sector and increased trading volume.

2026. g. 13. aug. 19:51 UTC

Haemonetics shares are declining amid rising jobless claims and flat Producer Price Index data, breaking a recent trend of higher daily closes.

2026. g. 12. aug. 20:01 UTC

Haemonetics Corp shares are higher today, supported by unusually high trading volume and a strong upward trajectory since Tuesday's close.

2026. g. 11. aug. 20:06 UTC

Haemonetics Corp shares are higher today, maintaining a position near the upper end of their one-month range despite a minor pullback earlier in the session.

2026. g. 10. aug. 19:46 UTC

Haemonetics Corp shares are declining amid broader market uncertainty following recent U.S. employment data, despite earlier gains during the session.

2026. g. 7. aug. 22:01 UTC

News

Haemonetics shares are lower in after-market trading despite Citigroup raising its price target to $92 and maintaining a Neutral rating.

2026. g. 6. aug. 21:01 UTC

Haemonetics Corp. shares are trading higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

2026. g. 5. aug. 19:31 UTC

Haemonetics Corp shares are lower today, breaking a trend of higher closes. The stock is experiencing unusually high trading volume amid no specific news.

2026. g. 4. aug. 21:01 UTC

Haemonetics Corp shares declined in after-market hours, despite broader market gains from positive U.S.-Iran negotiations and falling crude oil prices.

2026. g. 3. aug. 19:56 UTC

Haemonetics Corp shares are higher, reflecting broader market gains amid positive momentum in major tech stocks and easing geopolitical tensions.

2026. g. 31. jūl. 20:04 UTC

Haemonetics Corp shares are higher, with no specific news identified. The broader market has also gained since Thursday's close, recovering from earlier losses.

2026. g. 30. jūl. 19:48 UTC

Haemonetics Corp. shares are lower today, continuing a decline since Wednesday. The stock remains above its 20-day moving average despite recent downward movement.

2026. g. 29. jūl. 21:21 UTC

Haemonetics Corp shares are lower in after-market trading, reflecting broader declines in the equity market and Health Care Supplies sector amid rising oil prices.

2026. g. 28. jūl. 21:01 UTC

Haemonetics Corp shares are lower in after-market hours, following a broader market decline amid a significant drop in the Nikkei 225 Index.

2026. g. 27. jūl. 22:51 UTC

Haemonetics Corp shares are higher in after-market trading, supported by falling crude oil prices and strong performance above the 20-day moving average.

2026. g. 24. jūl. 20:31 UTC

Haemonetics Corp shares are lower in after-market hours, continuing a decline from Friday's close. No specific news was identified to explain the movement.

2026. g. 23. jūl. 23:21 UTC

Haemonetics Corp shares are lower in after-market trading, continuing a decline that began after Thursday's close, reaching the midpoint of their one-month trading range.

2026. g. 22. jūl. 20:13 UTC

Shares of Haemonetics Corp are trading higher in after-market hours, positioned above its 20-day moving average amid broader market volatility and rising crude oil prices.

2026. g. 20. jūl. 18:46 UTC

Haemonetics Corp shares are higher today, continuing gains since Friday's close. The stock reached a session high earlier, though it has pulled back.

Salīdzinājums

Cenas izmaiņa

Haemonetics Corp Prognoze

Cenas mērķis

By TipRanks

4.15% augšup

Prognoze 12 mēnešiem

Vidējais 94.13 USD 4.15%

Augstākais 105 USD

Zemākais 84 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Haemonetics Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Haemonetics Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

4 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.